BioSpace News Archive

Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.

Mineralys Therapeutics, Inc. today announced topline results from the Phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension.

Advantum Health, an industry-leading practice revenue management authority, announced the appointment of Tammy Taylor as Chief Executive Officer and Chris Taft as Chief Financial Officer.

A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor’s Biome proprietary blend of probiotics (10 lactobacilli and 5 bifidobacteria) in inhibition of Clostridium difficile (C. diff); a life-threatening diarrhea-causing bacteria.

BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHK Capital Disruptive Growth Conference in New York City.

Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma.

Epitomee Medical, a biomedical company, develops unique ingestible devices that deploy targeted therapies along the GI tract, to treat a variety of chronic diseases and metabolic disorders.

LongueVue Capital (“LVC”) is pleased to announce it has partnered with Pinnacle Clinical Research, LLC (“Pinnacle” or the “Company”), a multi-location site organization specializing in complex therapeutic areas, including hepatology with a focus on non-alcoholic fatty liver disease (“NAFLD”) and nonalcoholic steatohepatitis (“NASH”).

Blackrock Neurotech, a leading brain-computer interface company, revealed its next-generation neural interface, Neuralace™, this week at Society for Neuroscience 2022.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company’s common stock.